Claims
- 1. A non-invasive method of detecting a site of apoptosis in vivo in a subject, the method comprising:
administering a composition to the subject comprising a fluorochrome conjugated to a moiety that binds specifically to apoptotic cells, and obtaining a fluorescence image of at least part of the subject to detect the site of apoptosis in the subject.
- 2. The method of claim 1, wherein the moiety is a protein or an active fragment thereof.
- 3. The method of claim 2, wherein the protein is selected from the group consisting of annexin and synaptotagmin.
- 4. The method of claim 2, wherein the active fragment comprises the C2 domain of synaptotagmin.
- 5. The method of claim 1, wherein the moiety is an anti-aminophospholipid antibody or an active fragment thereof.
- 6. The method of claim 5, wherein the antibody is an anti-phosphatidylserine antibody or an active fragment thereof.
- 7. The method of claim 5, wherein the antibody is an anti-phosphatidylethanolamine antibody or an active fragment thereof.
- 8. The method of claim 1, wherein the fluorochrome fluoresces in the near-infrared region.
- 9. The method of claim 1, wherein the fluorochrome is selected from the group consisting of Cy5, Cy5.5, Cy7, ALEXA FLUOR 680, ALEXA FLUOR 700, ALEXA FLUOR 750, IRDye38, IRDye78, IRDye80, indocyanine green, LaJolla Blue, and Licor NIR.
- 10. The method of claim 1, wherein the subject is an animal.
- 11. The method of claim 1, wherein the subject is a mammal.
- 12. The method of claim 11, wherein the mammal is a mouse.
- 13. The method of claim 1, wherein the subject is a human.
- 14. The method of claim 1, wherein the administering is orally, parenterally, by inhalation, topically, rectally, nasally, buccally, vaginally, via an implanted reservoir, via a catheter, or through a needle to a tissue.
- 15. The method of claim 1, wherein the obtaining is by near-infrared fluorescence (NIRF) imaging.
- 16. The method of claim 1, wherein the NIRF imaging is fluorescence mediated tomography (FMT).
- 17. The method of claim 1, wherein the NIRF imaging is surface reflectance imaging.
- 18. The method of claim 1, wherein the NIRF imaging uses an endoscope.
- 19. A conjugate comprising:
a moiety that binds specifically to apoptotic cells, and a fluorochrome covalently bound to the moiety, wherein the moiety and the fluorochrome are present in a stoichiometry of at least 1:2.
- 20. The conjugate of claim 19, wherein the moiety is annexin or an active fragment thereof or synaptotagmin or an active fragment thereof.
- 21. The conjugate of claim 19, wherein the moiety is an anti-aminophospholipid antibody or active fragment thereof.
- 22. The conjugate of claim 19, wherein the fluorochrome emits near-infrared fluorescence.
- 23. The conjugate of claim 22, wherein the fluorochrome is selected from the group consisting of Cy5, Cy5.5, Cy7, ALEXA FLUOR 680, ALEXA FLUOR 700, ALEXA FLUOR 750, IRDye38, IRDye78, IRDye80, indocyanine green, LaJolla Blue, and Licor NIR.
- 24. A conjugate comprising annexin and a fluorochrome selected from the group consisting of ALEXA FLUOR 680, ALEXA FLUOR 700, ALEXA FLUOR 750, IRDye38, IRDye78, IRDye80, indocyanine green, LaJolla Blue, and Licor NIR.
- 25. A conjugate comprising synaptotagmin or an anti-aminophospholipid antibody and a fluorochrome selected from the group consisting of Cy5, Cy5.5, Cy7, ALEXA FLUOR 680, ALEXA FLUOR 700, ALEXA FLUOR 750, IRDye38, IRDye78, IRDye80, indocyanine green, LaJolla Blue, and Licor NIR.
- 26. The conjugate of claim 25, wherein the anti-aminophospholipid antibody is an anti-phosphatidylserine antibody.
- 27. The conjugate of claim 25, wherein the anti-aminophospholipid antibody is an anti-phosphatidylethanolamine antibody.
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority under 35 USC §119(e) to U.S. Patent Application Serial No. 60/376,052, filed on Apr. 26, 2002, the entire contents of which are hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60376052 |
Apr 2002 |
US |